At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
Latanoprostene bunoddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Latanoprostene bunod for Glaucoma and Ocular Hypertension. Completed, enrolled 130 participants across 1 site.
Detailed Summary
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionApr 2015
Study CompletionApr 2015
TodayJul 2026
First PostedJul 11, 2013
Enrollment StartJul 5, 2013
Primary CompletionApr 2, 2015
Study CompletionApr 14, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.0 years ago
Interventions
Latanoprostene bunoddrug